Sugi Predict

Sugi Predict / Targets / PDE9A

PDE9A

High affinity cGMP-specific 3',5'-cyclic phosphodiesterase 9A · O76083 · PDE9A on Sugi Atlas →

33,372 patent compounds predicted against PDE9A, 18,459 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
SCHEMBL1664897 SCHEMBL1664897 1.00 20/20
SCHEMBL877646 SCHEMBL877646 0.88 20/20
SCHEMBL877874 SCHEMBL877874 0.86 20/20
SCHEMBL877241 SCHEMBL877241 0.85 20/20
SCHEMBL882603 SCHEMBL882603 0.85 20/20
SCHEMBL877175 SCHEMBL877175 0.83 20/20
SCHEMBL877867 SCHEMBL877867 0.82 20/20
SCHEMBL878051 SCHEMBL878051 0.79 20/20
SCHEMBL876862 SCHEMBL876862 0.78 20/20
SCHEMBL883037 SCHEMBL883037 0.75 20/20
SCHEMBL876783 SCHEMBL876783 0.74 20/20
SCHEMBL877495 SCHEMBL877495 0.72 20/20
SCHEMBL882610 SCHEMBL882610 0.72 20/20
SCHEMBL876812 SCHEMBL876812 0.71 20/20
SCHEMBL876745 SCHEMBL876745 0.70 20/20
SCHEMBL876976 SCHEMBL876976 0.70 20/20
SCHEMBL877791 SCHEMBL877791 0.70 20/20
SCHEMBL882604 SCHEMBL882604 0.70 20/20
SCHEMBL882671 SCHEMBL882671 0.70 20/20
SCHEMBL534772 SCHEMBL534772 0.69 20/20

Clinical trials — most relevant to PDE9A by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Switching of Sildenafil to Riociguat in CTEPH Patients PHASE4RECRUITING
A Clinical Trial of Ambrisentan and Tadalafil in Pulmonary Arterial Hypertension Associated With Systemic Sclerosis PHASE4COMPLETED
Randomized, Controlled Trial of Regular Sildenafil Citrate in the Prevention of Altitude Illness PHASE4COMPLETED
Safety And Efficacy Of L-Arginine Monotherapy Versus Tadalafil Monotherapy Versus Their Combination In Men With Erectile Dysfunction; A Prospective Randomized Study PHASE4COMPLETED
Cardiovascular Effects of Chronic Sildenafil in Men With Type 2 Diabetes PHASE4COMPLETED
The Efficacy and Safety of Vardenafil in the Treatment of Pulmonary Arterial Hypertension PHASE3COMPLETED
Chronic Sildenafil Treatment in Heart Failure PHASE3COMPLETED
Use of Sildenafil Citrate in Management of Mild Pre-eclampsia PHASE2/PHASE3UNKNOWN
Cilostazol With Nimodipine to Improve Outcome After Aneurysmal Subarachnoid Hemorrhage PHASE3NOT_YET_RECRUITING
Sildenofil in Persistent Pulmonary Hypertension in Newborns PHASE3UNKNOWN
The Phosphodiesterase 4 Inhibitor Roflumilast as an Adjunct to Antidepressants in Major Depressive Disorder Patients PHASE1/PHASE2WITHDRAWN
Theophylline Treatment for Pseudohypoparathyroidism - Children 2-12 Years Old PHASE2ACTIVE_NOT_RECRUITING
Tadalafil for Pulmonary Hypertension Due to Chronic Lung Disease PHASE2COMPLETED
Safety Study of Sildenafil in Treatment of Cerebral Aneurysm Vasospasm PHASE2WITHDRAWN
Pentoxifylline as an Adjunctive in Treatment of Negative Symptoms in Chronic Schizophrenia PHASE1/PHASE2COMPLETED
Perfusion by Arterial Spin Labelling Following Single Dose Tadalafil in Small Vessel Disease (PASTIS) Trial PHASE2COMPLETED
A Trial for Prevention of Recurrent Ischemic Priapism in Men With Sickle Cell Disease: A Pilot Study PHASE2COMPLETED
Effect of Tadalafil on Cerebral Large Arteries in Stroke PHASE2COMPLETED
Title: Evaluation of a Novel PET Radioligand for Phosphodiesterase-4D (PDE4D) PHASE1/PHASE2COMPLETED
Safety, Tolerability, Pharmacokinetics, And Pharmacodynamics Study Of PF-04447943, Co-Administered With And Without Hydroxyurea, In Subjects With Stable Sickle Cell Disease PHASE1COMPLETED
Safety Study of the Effect of Scelectium Tortuosum (as Zembrin®)in Aged Normals PHASE1COMPLETED
Vitamin D Versus Sildenafil Citrate in Fetal Growth Restriction PHASE1COMPLETED
Sildenafil Citrate Added to Low Molecular Weight Heparin and Low Dose Aspirin in High-risk Pregnancy nanWITHDRAWN
Endurance Performance at Altitude nanCOMPLETED
Clinical Study for the Effectiveness of Roflumilast Treatment in COPD Greek Patients Based on Standard Clinical Practice. nanUNKNOWN
Safety and Efficacy of Tadalafil vs. Tadalafil With Sildosin in the Management of Moderately and Severely Symptomatic Patients of Prostatic Hyperplasia nanUNKNOWN
Platelet and Tissue cAMP: Novel Biomarkers of Milrinone Efficacy in Children nanCOMPLETED
Role of Nitric Oxide in Diabetic Patients With Erectile Dysfunction nanCOMPLETED
Silodosin, Tadalafil Alone vs. Silodosin Plus Tadalafil as MET for Lower Ureteric Stones nanCOMPLETED
Clinical Characterization on PDE6A-related Retinitis Pigmentosa in Preparation to a Gene Therapy Trial nanCOMPLETED

Related proteins — ESM-2 sequence neighbours (a PDE9A binder may also engage these)

ProteinNameSimilarity
H2QL32 — 1.000 H2QL32 →
O70628 — 1.000 O70628 →
Q8QZV1 — 1.000 Q8QZV1 →
PDE4B 3',5'-cyclic-AMP phosphodiesterase 4B 0.994 landscape →
P30645 — 0.994 P30645 →
P14646 — 0.994 P14646 →
E9Q4S1 — 0.992 E9Q4S1 →
PDE8B High affinity cAMP-specific and IBMX-insensitive 3',5'-cyclic phosphodiesterase 8B 0.991 landscape →
Q01063 — 0.991 Q01063 →
A2CEA7 — 0.990 A2CEA7 →
PDE8A High affinity cAMP-specific and IBMX-insensitive 3',5'-cyclic phosphodiesterase 8A 0.989 landscape →
D3ZA12 — 0.989 D3ZA12 →
KDM5B Lysine-specific demethylase 5B 0.989 landscape →
Q9H1H9 — 0.988 Q9H1H9 →
Q9AWM8 — 0.988 Q9AWM8 →
A3KFM7 — 0.988 A3KFM7 →
Q9XTJ4 — 0.988 Q9XTJ4 →
G5EFD2 — 0.988 G5EFD2 →
Q24592 — 0.988 Q24592 →
Q12756 — 0.988 Q12756 →
KAT8 Histone acetyltransferase KAT8 0.988 landscape →
Q5XI06 — 0.988 Q5XI06 →
Q04692 — 0.988 Q04692 →
H2KZW3 — 0.988 H2KZW3 →
B3H6Z8 — 0.988 B3H6Z8 →
O12990 — 0.988 O12990 →
A1ZAJ2 — 0.988 A1ZAJ2 →
Q19546 — 0.988 Q19546 →
Q9D3R6 — 0.987 Q9D3R6 →
O14827 — 0.987 O14827 →